Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
Public ClinicalTrials.gov record NCT01818752. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Study identification
- NCT ID
- NCT01818752
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 955 participants
Conditions and interventions
Conditions
Interventions
- Carfilzomib Drug
- Bortezomib Drug
- Melphalan Drug
- Prednisone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 7, 2013
- Primary completion
- Jul 14, 2016
- Completion
- Nov 3, 2016
- Last update posted
- Aug 25, 2019
2013 – 2016
United States locations
- U.S. sites
- 14
- U.S. states
- 8
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Cancer Associates for Research & Excellence, Inc. (cCARE) | Fresno | California | 93720 | — |
| Marin Cancer Care | Greenbrae | California | 94904 | — |
| Sutter Gould Medical Foundation | Modesto | California | 95357 | — |
| Innovative Clinical Research Institute | Whittier | California | 90603 | — |
| UF Health Shands Cancer Hospital | Gainesville | Florida | — | — |
| Evanston KelIogg Cancer Center | Evanston | Illinois | — | — |
| Billings Clinic Cancer Center | Billings | Montana | 59101 | — |
| Maimonides Cancer Center | Brooklyn | New York | — | — |
| Weill Cornell Medical Center | New York | New York | 10021 | — |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | — |
| Saint Francis Health System | Greenville | South Carolina | 29601 | — |
| Spartanburg Regional Healthcare System | Spartanburg | South Carolina | 29303 | — |
| Santee Hematology Oncology | Sumter | South Carolina | 29150 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 199 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01818752, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 25, 2019 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01818752 live on ClinicalTrials.gov.